Jawad Nazir, MD
Infectious Disease · Sioux Falls, SDNPI 1972579118
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $124 of the $153 with a category attached, or 81.1%. Melinta Therapeutics, LLC accounts for 81.1% of it on its own, with 2 other manufacturers making up the rest. 2023 is the largest year on record at $124, 9.8 times the $13 reported in 2019.
Across 3 payments — averaging $51.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Melinta Therapeutics, LLC$124
- Insmed, Inc.$16
- Merck$13
Across 124 payments — averaging $19,091 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2.2M
- Pfizer$132K
What the payments were for
- Food & beverage$12481%
- Education$2919%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Melinta Therapeutics, LLC | 1 | $124 |
| Insmed, Inc. | 1 | $16 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rezzayo$124
How this compares
$153 in reported general payments places this provider in the 55th percentile of 22 infectious disease providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 55 | $214,801 |
| Cefadroxil | 17 | $1,817 |
| Fluconazole | 12 | $1,069 |
| Doxycycline Hyclate | 28 | $997 |
| Ethambutol Hcl | 12 | $948 |
| Rifampin | 12 | $713 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 31 | $368 |
| Levofloxacin | 15 | $318 |
| ValacyclovirValacyclovir Hcl | 13 | $306 |
| Cephalexin | 25 | $238 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $230 |
| Penicillin V Potassium | 26 | $217 |
| Clindamycin Hcl | 12 | $178 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Sioux Falls
- Bertha AyiSioux Falls$692
- Robert KesslerSioux Falls$494
- Jose Suarez IsaacsSioux Falls$266
- Asma SyedSioux Falls$211
- Brian PepitoSioux Falls$153
- Emad Abu SittaSioux Falls$149
- Miguel Cervera HernandezSioux Falls$137
- Nirmal MuthukumarasamySioux Falls$105
- Gerard DavidSioux Falls$96
- Wendell HoffmanSioux Falls$89
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.